A clinical and economic assessment of adjuvanted trivalent versus standard egg-derived quadrivalent influenza vaccines among older adults in the United States during the 2018-19 and 2019-20 influenza seasons

References

• Czaja CA, Miller L, Alden N, et al. Age-related differences in hospitalization rates, clinical presentation, and outcomes among older adults hospitalized with influenza-U.S. Influenza hospitalization surveillance network (FluSurv-NET). Open Forum Infect Dis. 2019;6(7):ofz225. doi: 10.1093/ofid/ofz225
   PubMed Web of Science ®Google Scholar
• Estimated flu-related illnesses, medical visits, hospitalizations, and deaths in the United States — 2018–2019 flu season. Atlanta (GA): Centers for Disease Control and Prevention; 2021 [cited 2022 Dec 13]. Available from: https://www.cdc.gov/flu/about/burden/2018-2019.html
   Google Scholar
• Estimated flu-related illnesses, medical visits, hospitalizations, and deaths in the United States — 2019–2020 flu season. Atlanta (GA): Centers for Disease Control and Prevention; 2022 [cited 2022 Dec 13]. Available from: https://www.cdc.gov/flu/about/burden/2019-2020.html
   Google Scholar
• Glezen WP, Greenberg SB, Atmar RL, et al. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA. 2000;283(4):499–505. doi: 10.1001/jama.283.4.499
   PubMed Web of Science ®Google Scholar
• McElhaney JE. The unmet need in the elderly: designing new influenza vaccines for older adults. Vaccine. 2005;23(Suppl 1):S10–S25. doi: 10.1016/j.vaccine.2005.04.019
   PubMed Web of Science ®Google Scholar
• Grohskopf LA, Blanton LH, Ferdinands JM, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices - United States, 2022-23 influenza season. MMWR Recomm Rep. 2022;71(1):1–28. doi: 10.15585/mmwr.rr7101a1
   PubMedGoogle Scholar
• Demicheli V, Jefferson T, Di Pietrantonj C, et al. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev. 2018;2(2): CD004876. doi: 10.1002/14651858.CD004879.pub5
   Google Scholar
• Targonski PV, Jacobson RM, Poland GA. Immunosenescence: role and measurement in influenza vaccine response among the elderly. Vaccine. 2007;25(16):3066–3069. doi: 10.1016/j.vaccine.2007.01.025
   PubMed Web of Science ®Google Scholar
• Goronzy JJ, Weyand CM. Understanding immunosenescence to improve responses to vaccines. Nat Immunol. 2013;14(5):428–436. doi: 10.1038/ni.2588
   PubMed Web of Science ®Google Scholar
• Andrew MK, Shinde V, Ye L, et al. The importance of frailty in the assessment of influenza vaccine effectiveness against influenza-related hospitalization in elderly people. J Infect Dis. 2017;216(4):405–414. doi: 10.1093/infdis/jix282
   PubMed Web of Science ®Google Scholar
• Rondy M, El Omeiri N, Thompson MG, et al. Effectiveness of influenza vaccines in preventing severe influenza illness among adults: a systematic review and meta-analysis of test-negative design case-control studies. J Infect. 2017;75(5):381–394. doi: 10.1016/j.jinf.2017.09.010
   PubMed Web of Science ®Google Scholar
• Grohskopf LA, Alyanak E, Broder KR, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices - United States, 2019-20 influenza season. MMWR Recomm Rep. 2019;68(3):1–21. doi: 10.15585/mmwr.rr6803a1
   PubMed Web of Science ®Google Scholar
• Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices-United States, 2018-19 influenza season. MMWR Recomm Rep. 2018;67(3):1–20. doi: 10.15585/mmwr.rr6703a1
   PubMed Web of Science ®Google Scholar
• Frey SE, Reyes MR, Reynales H, et al. Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. Vaccine. 2014;32(39):5027–5034. doi: 10.1016/j.vaccine.2014.07.013
   PubMed Web of Science ®Google Scholar
• Nicolay U, Heijnen E, Nacci P, et al. Immunogenicity of aIIV3, MF59-adjuvanted seasonal trivalent influenza vaccine, in older adults ≥65 years of age: Meta-analysis of cumulative clinical experience. Int J Infect Dis. 2019;85:S1–S9. doi: 10.1016/j.ijid.2019.03.026
   PubMed Web of Science ®Google Scholar
• Boikos C, Fischer L, O’Brien D, et al. Relative effectiveness of adjuvanted trivalent inactivated influenza vaccine versus egg-derived quadrivalent inactivated influenza vaccines and high-dose trivalent influenza vaccine in preventing influenza-related medical encounters in US adults ≥ 65 years during the 2017-2018 and 2018-2019 influenza seasons. Clin Infect Dis. 2021;73(5):816–823. doi: 10.1093/cid/ciab152
   PubMed Web of Science ®Google Scholar
• Boikos C, Imran M, Nguyen VH, et al. Effectiveness of the adjuvanted influenza vaccine in older adults at high risk of influenza complications. Vaccines (Basel). 2021;9(8):862. doi: 10.3390/vaccines9080862
   PubMed Web of Science ®Google Scholar
• Izurieta HS, Chillarige Y, Kelman J, et al. Relative effectiveness of influenza vaccines among the United States elderly, 2018-2019. J Infect Dis. 2020;222(2):278–287. doi: 10.1093/infdis/jiaa080
   PubMed Web of Science ®Google Scholar
• Izurieta HS, Lu M, Kelman J, et al. Comparative effectiveness of influenza vaccines among US medicare beneficiaries ages 65 years and older during the 2019-2020 season. Clin Infect Dis. 2021;73(11):e4251–e4259. doi: 10.1093/cid/ciaa1727
   PubMed Web of Science ®Google Scholar
• Pelton SI, Divino V, Shah D, et al. Evaluating the relative vaccine effectiveness of adjuvanted trivalent influenza vaccine compared to high-dose trivalent and other egg-based influenza vaccines among older adults in the US during the 2017-2018 influenza season. Vaccines (Basel). 2020;8(3):446. doi: 10.3390/vaccines8030446
   PubMed Web of Science ®Google Scholar
• Coleman BL, Sanderson R, Haag MDM, et al. Effectiveness of the MF59-adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta-analysis. Influenza Other Respir Viruses. 2021;15(6):813–823. doi: 10.1111/irv.12871
   PubMed Web of Science ®Google Scholar
• Van Aalst R, Gravenstein S, Mor V, et al. Economic assessment of high-dose versus adjuvanted influenza vaccine: an evaluation of hospitalization costs based on a cohort study. Vaccines (Basel). 2021;9(10):1065. doi: 10.3390/vaccines9101065
   PubMed Web of Science ®Google Scholar
• Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661–3679. doi: 10.1002/sim.6607
   PubMed Web of Science ®Google Scholar
• Pelton SI, Divino V, Postma MJ, et al. A retrospective cohort study assessing relative effectiveness of adjuvanted versus high-dose trivalent influenza vaccines among older adults in the United States during the 2018-19 influenza season. Vaccine. 2021;39(17):2396–2407. doi: 10.1016/j.vaccine.2021.03.054
   PubMed Web of Science ®Google Scholar
• Levin MJ, Divino V, Shah D, et al. Comparing the clinical and economic outcomes associated with adjuvanted versus high-dose trivalent influenza vaccine among adults aged ≥ 65 years in the US during the 2019-20 influenza season-a retrospective cohort analysis. Vaccines (Basel). 2021;9(10):1146. doi: 10.3390/vaccines9101146
   PubMed Web of Science ®Google Scholar
• Huse D, Russo P, Vasey J. Expanding the evidence base in outcomes research: linking electronic medical records and claims data. ISPOR Connections. 2013;19(3):5–7.
   Google Scholar
• Dawood FS, Chung JR, Kim SS, et al. Interim estimates of 2019-20 seasonal influenza vaccine effectiveness - United States, February 2020. MMWR Morb Mortal Wkly Rep. 2020;69(7):177–182. doi: 10.15585/mmwr.mm6907a1
   PubMed Web of Science ®Google Scholar
• Xu X, Blanton L, Elal AIA, et al. Update: influenza activity in the United States during the 2018-19 season and composition of the 2019-20 influenza vaccine. MMWR Morb Mortal Wkly Rep. 2019;68(24):544–551. doi: 10.15585/mmwr.mm6824a3
   PubMed Web of Science ®Google Scholar
• Influenza-like illness, code set B. Falls Church (VA): US Armed Forces health Surveillance center; 2015 [cited 2023 Jul 25]. Available from: https://health.mil/Reference-Center/Publications/2015/10/01/Influenza-Like-Illness
   Google Scholar
• Romano PS, Roos LL, Jollis JG. Presentation adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993;46(10):1075–1079. discussion 1081–1090. doi: 10.1016/0895-4356(93)90103-8
   PubMed Web of Science ®Google Scholar
• Nuttall M, van der Meulen J, Emberton M. Charlson scores based on ICD-10 administrative data were valid in assessing comorbidity in patients undergoing urological cancer surgery. J Clin Epidemiol. 2006;59(3):265–273. doi: 10.1016/j.jclinepi.2005.07.015
   PubMed Web of Science ®Google Scholar
• Cost-to-charge ratio for inpatient files. Rockville (MD): Agency for Healthcare Research and Quality; 2021 [cited 2023 Jul 25]. Available from: https://hcup-us.ahrq.gov/db/ccr/ip-ccr/ip-ccr.jsp.
   Google Scholar
• Centers for Medicare and Medicaid Services. Medicare CY 2019 outpatient prospective payment system (OPPS) final rule claims accounting. (MD) United States: Centers for Medicare and Medicaid Services; 2019.
   Google Scholar
• Thoemmes F, Ong AD. A primer on inverse probability of treatment weighting and marginal structural models. Emerg Adulthood. 2015;4(1):40–59. doi: 10.1177/2167696815621645
   Google Scholar
• Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083–3107. doi: 10.1002/sim.3697
   PubMed Web of Science ®Google Scholar
• ReimbursementCodes features. RJ Health; [cited 2022 Dec 14]. Available from: https://www.reimbursementcodes.com/
   Google Scholar
• Lozalojo/Mem: second release of the MEM R library (v2.0). Lozano J. 2016 [cited 2022 Dec 14]. Available from. 10.5281/zenodo.165983
   Google Scholar
• Malosh RE, McGovern I, Monto AS. Influenza during the 2010-2020 decade in the United States: seasonal outbreaks and vaccine interventions. Clin Infect Dis. 2023;76(3):540–549. doi: 10.1093/cid/ciac653
   PubMed Web of Science ®Google Scholar
• Loong D, Pham B, Amiri M, et al. Systematic review on the cost-effectiveness of seasonal influenza vaccines in older adults. Value Health. 2022;25(8):1439–1458. doi: 10.1016/j.jval.2022.03.011
   PubMed Web of Science ®Google Scholar
• Olsen SJ, Azziz-Baumgartner E, Budd AP, et al. Decreased influenza activity during the COVID-19 pandemic-United States, Australia, Chile, and South Africa, 2020. Am J Transplant. 2020;20(12):3681–3685. doi: 10.1111/ajt.16381
   PubMed Web of Science ®Google Scholar
• Ansaldi F, Zancolli M, Durando P, et al. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. Vaccine. 2010;28(25):4123–4129. doi: 10.1016/j.vaccine.2010.04.030
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Ott GS, De Gregorio E, et al. The mechanism of action of MF59 - an innately attractive adjuvant formulation. Vaccine. 2012;30(29):4341–4348. doi: 10.1016/j.vaccine.2011.09.061
   PubMed Web of Science ®Google Scholar
• Grohskopf LA, Alyanak E, Broder KR, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices - United States, 2020-21 influenza season. MMWR Recomm Rep. 2020;69(8):1–24. doi: 10.15585/mmwr.rr6908a1
   PubMed Web of Science ®Google Scholar
• Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother. 2012;8(1):81–88. doi: 10.4161/hv.8.1.17623
   PubMed Web of Science ®Google Scholar